NDATRANSDERMALFILM, EXTENDED RELEASE
Approved
Feb 2003
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
20
Data completeness
5/8 — Partial
OXYTROL (oxybutynin) by AbbVie is cholinergic muscarinic antagonists [moa]. Approved for cholinergic muscarinic antagonist [epc]. First approved in 2003.
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
OXYTROL (oxybutynin) is a transdermal, extended-release small molecule that antagonizes cholinergic muscarinic receptors to reduce urinary incontinence and overactive bladder symptoms. It is delivered via a film patch applied to skin, offering an alternative to oral formulations. This anticholinergic mechanism reduces involuntary bladder contractions, providing symptomatic relief for patients with urge incontinence.
$0.002BPart D
LOE ApproachingLate-stage product with modest Part D spending ($2M, ~1,858 claims in 2023) signals a mature, stable franchise facing competitive pressure and imminent loss of exclusivity.
Mechanism of Action
Cholinergic Muscarinic Antagonists
Pharmacologic Class:
Cholinergic Muscarinic Antagonist
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (20)
Efficacy of Intravesical Oxybutynin in Children With Neurogenic Bladder Dysfunction
Started Jan 2026
60 enrolled
Spina Bifida
Testing the Effects of Oxybutynin for the Treatment of Hot Flashes in Men Receiving Hormone Therapy for Prostate Cancer
Started Oct 2021
88 enrolled
Prostate Carcinoma
Oxybutynin Chloride in Managing Hot Flashes
Started Dec 2016
150 enrolled
Breast CarcinomaDuctal Breast Carcinoma In SituHot Flashes+2 more
A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment
Started Aug 2016
47 enrolled
Overactive BladderMild Cognitive Impairment
A Pilot Study Exploring the Efficacy and Safety of Topical Oxybutynin 3% Gel for Primary Focal Hyperhidrosis in Adolescents and Young Adults
Started Feb 2016
10 enrolled
Hyperhidrosis
Worked on OXYTROL at AbbVie? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.